Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 6/20 | 0.75 |
| ▸ | MEN1 | O00255 | 5/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.75 |
| ▸ | MAPT | P10636 | 5/20 | 0.75 |
| ▸ | LMNA | P02545 | 5/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.75 |
| ▸ | HTT | P42858 | 3/20 | 0.75 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.75 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.75 |
| ▸ | HPGD | P15428 | 1/20 | 0.75 |
| ▸ | KDR | P35968 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.54 |
| ▸ | ABL1 | P00519 | 1/20 | 0.53 |
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
| ▸ | CSF1R | P07333 | 1/20 | 0.53 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.53 |
| ▸ | KIT | P10721 | 1/20 | 0.53 |
| ▸ | FLT1 | P17948 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3109871 | 0.83 | RXFP1 (0.81) | RXFP1MEN1KMT2AMAPTLMNA | |
| SCHEMBL3118645 | 0.83 | MEN1 (0.87) | RXFP1MEN1KMT2AMAPTLMNA | |
| Hydrochloric Acid SCHEMBL4405252 | 0.82 | RXFP1 (0.80) | RXFP1MEN1KMT2AMAPTLMNA | |
| SCHEMBL427615 | 0.80 | KDR (0.84) | RXFP1MEN1KMT2AMAPTLMNA | |
| SCHEMBL3106390 | 0.80 | KDR (0.70) | RXFP1MEN1KMT2AMAPTLMNA | |
| Hydrochloric Acid SCHEMBL447740 | 0.80 | KDR (0.83) | RXFP1MEN1KMT2AMAPTLMNA | |
| SCHEMBL3108619 | 0.79 | MEN1 (0.79) | RXFP1MEN1KMT2AMAPTLMNA | |
| SCHEMBL3122487 | 0.79 | RXFP1 (0.71) | RXFP1MEN1KMT2AMAPTLMNA | |
| SCHEMBL18070968 | 0.78 | RXFP1 (0.64) | RXFP1MEN1KMT2AMAPTLMNA | |
| SCHEMBL427736 | 0.78 | KDR (0.64) | RXFP1MEN1KMT2AMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1671700-A | Substituted alkylamine derivatives and methods of use | AMGEN INC (US) | 2005-09-21 | — | — | CN | claimed |
| US-8642624-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642624-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-8058445-B2 | Substituted pyridinecarboxamides for the treatment of cancer | AMGEN INC. (US) | 2011-11-15 | — | — | US | disclosed |
| US-7687643-B2 | Process for preparing 3,3-dimethylindolines | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-7687643-B2 | Process for preparing 3,3-dimethylindolines | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
| EP-1798230-A1 | Substituted alkylamine derivatives and methods of use | Amgen Inc. (US) | 2007-06-20 | — | — | EP | disclosed |
| CN-1671700-A | Substituted alkylamine derivatives and methods of use | AMGEN INC (US) | 2005-09-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AADAC, NAT1, PIGO | RXFP1 1784/4885MEN1 1584/4885KMT2A 1046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.